<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5530410</article-id><article-id pub-id-type="doi">10.1155/2017/5783719</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>CYP2C19<sup>&#x0204e;</sup>2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ruedlinger</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Prado</surname><given-names>Yalena</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zambrano</surname><given-names>Tom&#x000e1;s</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3334-5107</contrib-id><name><surname>Saavedra</surname><given-names>Nicol&#x000e1;s</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bobadilla</surname><given-names>Braulio</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Potthoff</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;rez</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lanas</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5112-6944</contrib-id><name><surname>Salazar</surname><given-names>Luis A.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco, Chile</aff><aff id="I2">
<sup>2</sup>Department of Internal Medicine, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile</aff><aff id="I3">
<sup>3</sup>Facultad de Medicina, Universidad de Concepci&#x000f3;n, Concepci&#x000f3;n, Chile</aff><author-notes><corresp id="cor1">*Luis A. Salazar: <email>luis.salazar@ufrontera.cl</email></corresp><fn fn-type="other"><p>Academic Editor: Stelvio M. Bandiera</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>13</day><month>7</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>5783719</elocation-id><history><date date-type="received"><day>1</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Jenny Ruedlinger et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p> Clopidogrel is an antiplatelet drug especially used in patients undergoing percutaneous coronary interventions (PCI). Polymorphisms within<italic> CYP2C19</italic> can result in important interindividual variations regarding therapeutic efficacy. Therefore, we aimed to evaluate the impact of the CYP2C19<sup>&#x0204e;</sup>2 variant (rs4244285) on in-stent restenosis occurrence in Chilean patients who underwent PCI and received clopidogrel. A total of 77 cases with stenosis &#x0003e;50% in the angioplasty site (62.75 &#x000b1; 9.8 years, 80.5% males) and 86 controls (65.45 &#x000b1; 9.8 years, 72.1% males) were studied. The polymorphism was genotyped using TaqMan&#x000ae; Drug Metabolism Genotyping Assays. Overall, CYP2C19<sup>&#x0204e;</sup>2 allele frequency was 8.3%. Diabetes, chronic lesions, and bare metal stents (BMS) were observed more often in cases than in controls (<italic>p</italic> = 0.05,<italic> p</italic> = 0.04, and<italic> p</italic> = 0.02, resp.). Genotypic frequencies did not differ significantly between the groups (<italic>p</italic> = 0.15). Nonetheless, the mutated allele was observed in a greater proportion in patients without in-stent restenosis (<italic>p</italic> = 0.055). There was no significant association between the rs4244285 variant and the occurrence of in-stent restenosis after PCI (OR = 0.44; 95% CI: 0.19 to 1.04;<italic> p</italic> = 0.06). In summary, no association was identified between the CYP2C19<sup>&#x0204e;</sup>2 variant and the development of coronary in-stent restenosis.</p></abstract><funding-group><award-group><funding-source>Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico</funding-source><award-id>1141292</award-id></award-group><award-group><funding-source>University of La Frontera</funding-source><award-id>DI13-0012</award-id><award-id>DI15-2021</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Clopidogrel is an antiplatelet drug widely used to reduce the risk of acute myocardial infarction and stroke, as well as for secondary prevention of atherosclerotic events in patients at high risk [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. This drug is often administered with aspirin as dual antiplatelet therapy (DAPT) in patients undergoing coronary angioplasty with stent implantation [<xref rid="B3" ref-type="bibr">3</xref>]. Clopidogrel is an inactive prodrug that requires liver activation by the cytochrome P450 enzyme complex, with CYP2C19 being one of the main enzymes involved in this process [<xref rid="B4" ref-type="bibr">4</xref>]. The active metabolite binds irreversibly to the P2Y12 receptor, inhibiting adenosine diphosphate- (ADP-) mediated platelet activation and aggregation [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>
<italic>CYP2C19</italic> polymorphisms have been previously associated with large interindividual variations in terms of therapeutic efficacy in patients treated with clopidogrel [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. Different allelic variants of this gene have been identified, demonstrating that its activity may be normal, reduced, or increased according to the allele detected [<xref rid="B9" ref-type="bibr">9</xref>]. CYP2C19<sup><italic>&#x02217;</italic></sup>2 corresponds to a change of guanine by adenine at position 681 in exon 5 and results in a loss-of-function allele associated with decreased conversion of clopidogrel to its active metabolite, increased platelet reactivity during therapy, and poor clinical outcome, with a potential increase of in-stent thrombosis [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. On the contrary, the CYP2C19<sup><italic>&#x02217;</italic></sup>17 variant is associated with increased antiplatelet therapeutic response and a better clinical outcome [<xref rid="B11" ref-type="bibr">11</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>]. Additionally, reports show that clopidogrel can prevent restenosis occurrence, partly due to the fact that inhibition of platelet activity would in turn decrease the release of platelet-derived growth factor (PDGF) [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>], which is a potent stimulator of vascular smooth muscle cell (VSMC) proliferation and cell migration [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Currently in the USA, patients with a poor metabolizer phenotype (<sup><italic>&#x02217;</italic></sup>2/<sup><italic>&#x02217;</italic></sup>2, <sup><italic>&#x02217;</italic></sup>2/<sup><italic>&#x02217;</italic></sup>3, and <sup><italic>&#x02217;</italic></sup>3/<sup><italic>&#x02217;</italic></sup>3) are advised to use drugs such as prasugrel and ticagrelor [<xref rid="B17" ref-type="bibr">17</xref>]; however, in Chile, information regarding the prevalence of CYP2C19 polymorphisms is still lacking. Since CYP2C19 is one of the main enzymes involved in hepatic bioactivation of clopidogrel, the polymorphic allele frequency of the CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant was determined in Chilean patients with coronary disease, evaluating its role in the occurrence of in-stent restenosis.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Study Population</title><p>This work corresponds to an incident unpaired case-control investigation. The presence of the CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant (rs4244285, 681G&#x0003e;A) was determined in 163 unrelated Chilean patients with coronary heart disease (CHD) admitted to the respective cardiology service of Dr. Hern&#x000e1;n Henr&#x000ed;quez Aravena Hospital (Temuco) or Dr. Guillermo Grant Benavente Hospital (Concepci&#x000f3;n), both in Chile. Patients underwent a successful PTCA and a coronary angiography control after 6 months, and all received DAPT. Patients with stenosis &#x0003e;50% were defined as cases and those with stenosis &#x0003c;50% were defined as controls by two experienced cardiologists. In total, both groups consisted of 77 cases and 86 controls. A record of demographic and anthropometric data, occurrence of myocardial infarction, presence of diabetes, biochemical tests (lipid profile, blood glucose, glycosylated hemoglobin, and serum creatinine), and smoking was elaborated, in addition to angiographic variables of the affected vessel, lesion characteristics, and stent type. The study protocol was approved by 2 independent ethics committees: Scientific Ethics Committee of Universidad de La Frontera and the Scientific Ethics Committee of the Health Service in Concepci&#x000f3;n. All individuals signed informed consent.</p></sec><sec id="sec2.2"><title>2.2. Samples Collection, DNA Extraction, and CYP2C19<sup><italic>&#x02217;</italic></sup>2 Genotyping</title><p>Blood samples used for biochemical determination and DNA extraction were obtained by venipuncture following 10&#x02013;12 hours of fasting. Genomic DNA was extracted from leukocytes by a method optimized by Salazar et al. [<xref rid="B18" ref-type="bibr">18</xref>]. DNA quantification and purity were assessed by UV spectrophotometry using a microplate reader (Infinite&#x000ae; 200PRO NanoQuant, Tecan). The rs4244285 SNP was genotyped by Real-Time Polymerase Chain Reaction (RT-PCR) assay using the C_25986767_70 TaqMan Drug Metabolism Genotyping Assay (Life Technologies, CA, USA). Data were analyzed with the StepOne software v2.3. Genotyping was performed using the allelic discrimination plot issued after PCR amplification. No template controls (NTC) were included to assess the presence of contaminants.</p></sec><sec id="sec2.3"><title>2.3. Statistical Analysis</title><p>Data are presented as percentages and means &#x000b1; standard deviation (SD). The differences between the means of two continuous variables were compared using two-tailed Student's <italic>t</italic>-test for unpaired samples when normal distribution of data was observed, according to D'Agostino testing, or by the nonparametric Mann&#x02013;Whitney <italic>U</italic> test. To determine differences between noncontinuous variables, genotypic distribution, allele frequencies, and Hardy-Weinberg equilibrium, chi-square test (<italic>&#x003c7;</italic><sup>2</sup>) was used. The association between restenosis and the CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant was estimated by calculating the odds ratio (OR) with a confidence interval (CI) of 95%. Additionally, a stratified Mantel-Haenszel analysis was performed to identify potentially confounding variables. A <italic>p</italic> value less than 0.05 was considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Clinical and Demographical Variables</title><p>Clinical, anthropometric, and laboratory characteristics of the studied subjects are shown in <xref ref-type="table" rid="tab1">Table 1</xref>. The average age of the control group was 65.45 &#x000b1; 9.8 years, whereas in the cases it was 62.75 &#x000b1; 9.8 years (<italic>p</italic> = 0.08). A majority of male patients were observed in both groups (80.5% cases and 72.1% controls, <italic>p</italic> = 0.2). No significant differences regarding demographic parameters, smoking, body mass index (BMI), and blood pressure were observed. On the other hand, diabetes was more frequent in cases than in controls (42% and 27%, resp.; <italic>p</italic> = 0.05) (<xref ref-type="table" rid="tab1">Table 1</xref>).</p></sec><sec id="sec3.2"><title>3.2. Angiographic Characteristics</title><p>
<xref ref-type="table" rid="tab2">Table 2</xref> shows angiographic parameters of the study group according to the development of in-stent restenosis. Length (21.5 &#x000b1; 5.4&#x02009;mm in cases versus 21.4 &#x000b1; 5.4&#x02009;mm in controls, <italic>p</italic> = 0.92) and diameter (3.0 &#x000b1; 0.45&#x02009;mm in cases versus 2.9 &#x000b1; 0.3&#x02009;mm in controls, <italic>p</italic> = 0.95) values were comparable between the two groups. On the other hand, a higher proportion of subjects with chronic lesions developed restenosis than patients with acute lesions (<italic>p</italic> = 0.042). Moreover, when comparing stent types (BMS versus DES), the presence of BMS in the case group was significantly higher than in controls (87.0% versus 72.3%, <italic>p</italic> = 0.019).</p></sec><sec id="sec3.3"><title>3.3. CYP2C19<sup><italic>&#x02217;</italic></sup>2 and In-Stent Restenosis</title><p>Considering the total cohort, allele frequency for the CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant was 8.3% (data not shown). Genotypic distribution and allelic frequencies for each group are shown in <xref ref-type="table" rid="tab3">Table 3</xref>. Genotype frequencies observed were consistent with Hardy-Weinberg equilibrium in cases (GG: 89.6%; AG: 10.4%; AA: 0.0%, <italic>&#x003c7;</italic><sup>2</sup> = 0.23, <italic>p</italic> = NS) and controls (GG: 79.0%; AG: 19.8%; AA: 1.2%, <italic>&#x003c7;</italic><sup>2</sup> = 0.002, <italic>p</italic> = NS). The minor allele was present in a greater proportion in the control group versus cases (10% versus 5%, resp.). No significant differences were observed in genotype frequencies between patients with restenosis and controls (<italic>p</italic> = 0.15). A higher minor allele frequency (MAF) was observed in patients who did not develop in-stent restenosis, though not significant (<italic>p</italic> = 0.055), with an odds ratio of 0.44 (95% CI: 0.19 to 1.04; <italic>p</italic> = 0.06). Since no patients from the case group carried the homozygous variant, and just one individual presented this genotype in the control group, we were unable to study more profoundly the isolated effect of the AA genotype on restenosis development. However, we observed that individuals from the control group carrying the mutated allele and receiving clopidogrel developed significantly less in-stent restenosis during the study period, discarding diabetes as a possible confounding variable by a stratified and adjusted Mantel-Haenszel analysis.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Sequence alterations in<italic> CYP2C19</italic> have been widely associated with therapeutic response variability to multiple drugs, as published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and reported as a warning by the FDA within Plavix (clopidogrel) indications [<xref rid="B17" ref-type="bibr">17</xref>]. It has been seriously recommended to consider<italic> CYP2C19</italic> genotypes in patients undergoing percutaneous coronary intervention (PCI), mainly due to the presence of loss-of-function alleles, which can result in subjects with a poor metabolizer phenotype who, therefore, should receive an alternative to clopidogrel therapy. This work constitutes the first study evaluating the association between the loss-of-function CYP2C19<sup><italic>&#x02217;</italic></sup>2 allele and the presence of in-stent restenosis in Chilean CAD patients. Our results show a MAF of 8.3% for the CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant in the entire study group and 5% and 10% allelic distribution in cases and controls, respectively. Allelic frequency for this variant was previously reported to reach 12% for Chileans in a study including the general population [<xref rid="B19" ref-type="bibr">19</xref>]. Both frequencies are lower than observed for Caucasians and Africans (15%) or Asians (29&#x02013;35%) [<xref rid="B17" ref-type="bibr">17</xref>]; however, our study reports a very similar frequency to countries such as Bolivia (7.8%) [<xref rid="B20" ref-type="bibr">20</xref>], Colombia (8.7%) [<xref rid="B21" ref-type="bibr">21</xref>], and Mexico (9.7%) [<xref rid="B22" ref-type="bibr">22</xref>] as well as Canadian native inhabitants (8.8%) [<xref rid="B23" ref-type="bibr">23</xref>]. Moreover, CYP2C19<sup><italic>&#x02217;</italic></sup>2 MAF obtained is comparable to different African populations such as Egyptians (10.9%) [<xref rid="B24" ref-type="bibr">24</xref>], Tanzanians (10%) [<xref rid="B25" ref-type="bibr">25</xref>], and Tunisians (10.5%) [<xref rid="B26" ref-type="bibr">26</xref>]; European populations such as Belgians (9.1%) [<xref rid="B27" ref-type="bibr">27</xref>]; and also Middle Eastern populations like Iranians (11.1%) [<xref rid="B28" ref-type="bibr">28</xref>] and Palestinians (9%) [<xref rid="B29" ref-type="bibr">29</xref>].</p><p>On the other hand, our results indicate a lack of association between the loss-of-function variant and restenosis development in the studied subjects. The relationship between low clopidogrel response and restenosis has been previously discarded in a study reporting that low platelet response to clopidogrel had no significant impact on restenosis after DES implantation [<xref rid="B30" ref-type="bibr">30</xref>]. However, there are reports indicating that there is a relationship with thrombus formation, raised by Oikawa et al. under the term &#x0201c;thromborestenosis,&#x0201d; mainly observed in sirolimus-eluting stents [<xref rid="B31" ref-type="bibr">31</xref>]. Nishio et al. [<xref rid="B32" ref-type="bibr">32</xref>] reported a higher incidence of target lesion revascularization (TLR) in patients classified as poor metabolizers, including genotype 2<sup><italic>&#x02217;</italic></sup>/2<sup><italic>&#x02217;</italic></sup>, and in intermediate metabolizers compared to extensive metabolizers (1<sup><italic>&#x02217;</italic></sup>/1<sup><italic>&#x02217;</italic></sup>) (<italic>p</italic> = 0.008). Sawada et al. [<xref rid="B33" ref-type="bibr">33</xref>] described that even though TLR is likely to be higher in carriers versus noncarriers of the 2<sup><italic>&#x02217;</italic></sup> allele, it did not reach statistical significance (<italic>p</italic> = 0.06), which did occur when comparing the presence of subclinical thrombi, more frequent in the first group (<italic>p</italic> = 0.0002). Our data indicate a higher proportion of the mutated allele in patients who did not develop restenosis (<italic>p</italic> = 0.055; OR: 0.44, <italic>p</italic> = 0.06). Even though these results are similar to those reported by Nozari et al. [<xref rid="B34" ref-type="bibr">34</xref>], as they could not establish a higher risk between carrying the CYP2C19<sup><italic>&#x02217;</italic></sup>2 allele and in-stent restenosis occurrence, the elevated frequency of the mutated allele in controls rather than cases represents a controversial and unexpected finding, mainly due to the fact that several studies identify this polymorphism as a risk variant. However, various interethnic studies have also demonstrated the highly polymorphic nature of<italic> CYP2C19</italic>, which could partly explain the differences observed between different populations, especially for the higher MAF found in control subjects from our study. In line with this, a previous 2012 case-control investigation performed in the Korean population described that patients with essential hypertension (EH) had a lower frequency of the CYP2C19<sup><italic>&#x02217;</italic></sup>3 variant allele than did normal controls [<xref rid="B35" ref-type="bibr">35</xref>], which is similar to the particular allele distribution reported by our group. Thus, special attention must be paid to race, as it seems to play a determinant role for the interpretation of the studies involving this variant.</p><p>Contrasting our results, a Chinese investigation established that loss-of-function<italic> CYP2C19</italic> genotypes (<sup><italic>&#x02217;</italic></sup>2/<sup><italic>&#x02217;</italic></sup>2, <sup><italic>&#x02217;</italic></sup>2/<sup><italic>&#x02217;</italic></sup>3, and <sup><italic>&#x02217;</italic></sup>3/<sup><italic>&#x02217;</italic></sup>3) represent risk factors for restenosis in patients with stenting in the vertebral artery (<italic>p</italic> = 0.001) [<xref rid="B36" ref-type="bibr">36</xref>]. Another important factor to consider corresponds to the effect of clinical and angiographic variables. A significant difference was observed in the number of cases with diabetes mellitus versus controls. Although it has been well established that diabetes constitutes one of the main clinical predictors of restenosis [<xref rid="B37" ref-type="bibr">37</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>], it has also been shown that diabetic patients have a lower response to clopidogrel and have lower levels of the circulating active metabolite [<xref rid="B40" ref-type="bibr">40</xref>], demonstrating also an increase in platelet reactivity and increased risk of thrombotic events [<xref rid="B41" ref-type="bibr">41</xref>]. In a recent study performed on patients with a coronary disease, it was determined that diabetics, CYP2C19<sup><italic>&#x02217;</italic></sup>2 phenotype carriers or both, required a 2&#x02013;4-fold higher clopidogrel dose to obtain similar platelet reactivity to patients medicated with 75&#x02009;mg having neither diabetes nor the loss-of-function variant [<xref rid="B42" ref-type="bibr">42</xref>]. With regard to the angiographic characteristics of the patients, a higher proportion of DES was observed in the control group, which has been abundantly associated with lower restenosis rates, namely, 5&#x02013;10%, versus 20&#x02013;30% when using BMS [<xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>].</p><p>Among the limitations of our work, we can find the restricted sample size, creating the need to replicate this study in a larger cohort. Additionally, we cannot exclude that different<italic> CYP2C19 </italic>variants not included in this study are present, such as CYP2C19<sup><italic>&#x02217;</italic></sup>17, which in combination with a loss-of-function variant results in an intermediate phenotype and not in poor drug metabolism.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>In summary, no association was found between the loss-of-function CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant and in-stent restenosis development. Although our results provide valuable information regarding the prevalence of this variant in the Chilean population, the greater proportion of mutated alleles in controls versus cases is to some extent contradictory. However, this outcome should be interpreted with caution, since additional clinical and angiographic factors found in the case group may predispose importantly to restenosis development, particularly in the case of diabetics.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by grants from FONDECYT (Chile) (1141292) and DIUFRO projects (DI13-0012 and DI15-2021), University of La Frontera. Jenny Ruedlinger was the recipient of a fellowship from CONICYT, Chile.</p></ack><sec><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fintel</surname><given-names>D. J.</given-names></name></person-group><article-title>Antiplatelet therapy in cerebrovascular disease: implications of the management of artherothrombosis with clopidogrel in high-risk patients and the clopidogrel for high artherothrombotic risk and ischemic stabilization, management, and avoidance studies' results for cardiologists</article-title><source><italic>Clinical Cardiology</italic></source><year>2007</year><volume>30</volume><issue>12</issue><fpage>604</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1002/clc.20154</pub-id><pub-id pub-id-type="other">2-s2.0-37349042496</pub-id><pub-id pub-id-type="pmid">17847044</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>M.</given-names></name><name><surname>Seip</surname><given-names>R. L.</given-names></name><name><surname>Gupta</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance</article-title><source><italic>Connecticut Medicine</italic></source><year>2012</year><volume>76</volume><issue>5</issue><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="other">2-s2.0-84861494626</pub-id><pub-id pub-id-type="pmid">22685981</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>S. R.</given-names></name><name><surname>Yusuf</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>R. J. G.</given-names></name><etal/></person-group><article-title>Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study</article-title><source><italic>The Lancet</italic></source><year>2001</year><volume>358</volume><issue>9281</issue><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)05701-4</pub-id><pub-id pub-id-type="other">2-s2.0-0035908781</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation</article-title><source><italic>Pharmacogenomics Journal</italic></source><year>2015</year><volume>15</volume><issue>1</issue><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="other">2-s2.0-84921844651</pub-id><pub-id pub-id-type="doi">10.1038/tpj.2014.30</pub-id><pub-id pub-id-type="pmid">25001882</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>N.</given-names></name><name><surname>Corsini</surname><given-names>A.</given-names></name><name><surname>Bellosta</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacology of the new P2Y12 receptor inhibitors: Insights on pharmacokinetic and pharmacodynamic properties</article-title><source><italic>Drugs</italic></source><year>2013</year><volume>73</volume><issue>15</issue><fpage>1681</fpage><lpage>1709</lpage><pub-id pub-id-type="other">2-s2.0-84887222370</pub-id><pub-id pub-id-type="doi">10.1007/s40265-013-0126-z</pub-id><pub-id pub-id-type="pmid">24114622</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmsze</surname><given-names>A.</given-names></name><name><surname>Van Werkum</surname><given-names>J. W.</given-names></name><name><surname>Bouman</surname><given-names>H. J.</given-names></name><etal/></person-group><article-title>Besides CYP2C19&#x02217;2, the variant allele CYP2C9&#x02217;3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation</article-title><source><italic>Pharmacogenetics and Genomics</italic></source><year>2010</year><volume>20</volume><issue>1</issue><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1097/FPC.0b013e328333dafe</pub-id><pub-id pub-id-type="other">2-s2.0-73949119561</pub-id><pub-id pub-id-type="pmid">19934793</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viveros</surname><given-names>M. E.</given-names></name><name><surname>Are&#x000e1;n</surname><given-names>C.</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients</article-title><source><italic>Archivos de Cardiologia de Mexico</italic></source><year>2016</year><volume>86</volume><issue>4</issue><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="other">2-s2.0-84995700019</pub-id><pub-id pub-id-type="doi">10.1016/j.acmx.2016.01.007</pub-id><pub-id pub-id-type="pmid">26971130</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W.-Y.</given-names></name><name><surname>Zhao</surname><given-names>T.</given-names></name><name><surname>Xiong</surname><given-names>X.-Y.</given-names></name><etal/></person-group><article-title>Association of CYP2C19 polymorphisms with the clinical efficacy of clopidogrel therapy in patients undergoing carotid artery stenting in Asia</article-title><source><italic>Scientific Reports</italic></source><year>2016</year><volume>6</volume><pub-id pub-id-type="publisher-id">25478</pub-id><pub-id pub-id-type="doi">10.1038/srep25478</pub-id><pub-id pub-id-type="other">2-s2.0-84966297470</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosdidier</surname><given-names>C.</given-names></name><name><surname>Quilici</surname><given-names>J.</given-names></name><name><surname>Loosveld</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of CYP2C19&#x02217;2 and &#x02217;17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications</article-title><source><italic>American Journal of Cardiology</italic></source><year>2013</year><volume>111</volume><issue>7</issue><fpage>985</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.12.013</pub-id><pub-id pub-id-type="other">2-s2.0-84875225074</pub-id><pub-id pub-id-type="pmid">23340030</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>Y.-H.</given-names></name><name><surname>Tantry</surname><given-names>U. S.</given-names></name><name><surname>Kim</surname><given-names>I.-S.</given-names></name><etal/></person-group><article-title>Effect of CYP2C19&#x02217;2 and &#x02217;23 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin</article-title><source><italic>Circulation: Cardiovascular Interventions</italic></source><year>2011</year><volume>4</volume><issue>6</issue><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.111.962555</pub-id><pub-id pub-id-type="other">2-s2.0-84862908606</pub-id><pub-id pub-id-type="pmid">22045970</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fr&#x000e9;re</surname><given-names>C.</given-names></name><name><surname>Cuisset</surname><given-names>T.</given-names></name><name><surname>Gaborit</surname><given-names>B.</given-names></name><name><surname>Alessi</surname><given-names>M.-C.</given-names></name><name><surname>Hulot</surname><given-names>J.-S.</given-names></name></person-group><article-title>The CYP2C19&#x02217;17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome</article-title><source><italic>Journal of Thrombosis and Haemostasis</italic></source><year>2009</year><volume>7</volume><issue>8</issue><fpage>1409</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03500.x</pub-id><pub-id pub-id-type="other">2-s2.0-67949120411</pub-id><pub-id pub-id-type="pmid">19496924</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiroch</surname><given-names>K. A.</given-names></name><name><surname>Sibbing</surname><given-names>D.</given-names></name><name><surname>Koch</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Protective effect of the CYP2C19&#x02217;17 polymorphism with increased activation of clopidogrel on cardiovascular events</article-title><source><italic>American Heart Journal</italic></source><year>2010</year><volume>160</volume><issue>3</issue><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2010.06.039</pub-id><pub-id pub-id-type="other">2-s2.0-77956353400</pub-id><pub-id pub-id-type="pmid">20826260</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>R. S.</given-names></name><name><surname>Nielsen</surname><given-names>F.</given-names></name><name><surname>Stage</surname><given-names>T. B.</given-names></name><etal/></person-group><article-title>CYP2C19&#x02217;17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel</article-title><source><italic>Clinical and Experimental Pharmacology and Physiology</italic></source><year>2014</year><volume>41</volume><issue>11</issue><fpage>870</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.12297</pub-id><pub-id pub-id-type="other">2-s2.0-84911887265</pub-id><pub-id pub-id-type="pmid">25115434</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>A. M.</given-names></name><name><surname>Brittenden</surname><given-names>J.</given-names></name><name><surname>Bachoo</surname><given-names>P.</given-names></name><name><surname>Ford</surname><given-names>I.</given-names></name><name><surname>Nixon</surname><given-names>G. F.</given-names></name></person-group><article-title>Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty</article-title><source><italic>Journal of Vascular Surgery</italic></source><year>2009</year><volume>50</volume><issue>4</issue><fpage>861</fpage><lpage>869</lpage><pub-id pub-id-type="other">2-s2.0-70349310078</pub-id><pub-id pub-id-type="doi">10.1016/j.jvs.2009.06.017</pub-id><pub-id pub-id-type="pmid">19786240</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>O.</given-names></name><name><surname>Brekke</surname><given-names>M.</given-names></name><name><surname>Seljeflot</surname><given-names>I.</given-names></name><name><surname>Semb</surname><given-names>A. G.</given-names></name><name><surname>Arnesen</surname><given-names>H.</given-names></name></person-group><article-title>Blood platelet count and reactivity are associated with restenosis 6 months after coronary angioplasty</article-title><source><italic>Scandinavian Cardiovascular Journal</italic></source><year>2004</year><volume>38</volume><issue>4</issue><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="other">2-s2.0-4444225018</pub-id><pub-id pub-id-type="doi">10.1080/14017430410035494</pub-id><pub-id pub-id-type="pmid">15553931</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>G. K.</given-names></name><name><surname>Kumar</surname><given-names>M. S.</given-names></name><name><surname>Wamhoff</surname><given-names>B. R.</given-names></name></person-group><article-title>Molecular regulation of vascular smooth muscle cell differentiation in development and disease</article-title><source><italic>Physiological Reviews</italic></source><year>2004</year><volume>84</volume><issue>3</issue><fpage>767</fpage><lpage>801</lpage><pub-id pub-id-type="other">2-s2.0-3042588831</pub-id><pub-id pub-id-type="doi">10.1152/physrev.00041.2003</pub-id><pub-id pub-id-type="pmid">15269336</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>S. A.</given-names></name><name><surname>Sangkuhl</surname><given-names>K.</given-names></name><name><surname>Stein</surname><given-names>C. M.</given-names></name><etal/></person-group><article-title>Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update</article-title><source><italic>Clinical Pharmacology and Therapeutics</italic></source><year>2013</year><volume>94</volume><issue>3</issue><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="other">2-s2.0-84883170442</pub-id><pub-id pub-id-type="doi">10.1038/clpt.2013.105</pub-id><pub-id pub-id-type="pmid">23698643</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>L. A.</given-names></name><name><surname>Melo</surname><given-names>C. E.</given-names></name><name><surname>Cavalli</surname><given-names>S. A.</given-names></name><name><surname>Hinuy</surname><given-names>H. M.</given-names></name><name><surname>Hirata</surname><given-names>M. H.</given-names></name><name><surname>Hirata</surname><given-names>R. D.</given-names></name></person-group><article-title>Microm&#x000e9;todo para extra&#x000e7;&#x000e3;o de DNA gen&#x000f4;mico &#x000fa;til no diagn&#x000f3;stico molecular da hipercolesterolemia familial</article-title><source><italic>Revista Brasileira de An&#x000e1;lises Cl&#x000ed;nicas</italic></source><year>2001</year><volume>33, article 6</volume></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roco</surname><given-names>&#x000c1;.</given-names></name><name><surname>Qui&#x000f1;ones</surname><given-names>L.</given-names></name><name><surname>Ag&#x000fa;ndez</surname><given-names>J. A. G.</given-names></name><etal/></person-group><article-title>Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations</article-title><source><italic>Frontiers in Genetics</italic></source><year>2012</year><volume>3</volume><pub-id pub-id-type="publisher-id">Article 229</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2012.00229</pub-id><pub-id pub-id-type="other">2-s2.0-84876145967</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo-Villalta</surname><given-names>H. V.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Bay&#x000e1;</surname><given-names>A.</given-names></name><name><surname>Okada</surname><given-names>Y.</given-names></name><name><surname>Horiuchi</surname><given-names>R.</given-names></name></person-group><article-title>Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study</article-title><source><italic>European Journal of Clinical Pharmacology</italic></source><year>2005</year><volume>61</volume><issue>3</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s00228-004-0890-5</pub-id><pub-id pub-id-type="other">2-s2.0-20044382860</pub-id><pub-id pub-id-type="pmid">15776277</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaza</surname><given-names>C.</given-names></name><name><surname>Henao</surname><given-names>J.</given-names></name><name><surname>Isaza Mart&#x000ed;nez</surname><given-names>J. H.</given-names></name><name><surname>Sep&#x000fa;lveda Arias</surname><given-names>J. C.</given-names></name><name><surname>Beltr&#x000e1;n</surname><given-names>L.</given-names></name></person-group><article-title>Phenotype-genotype analysis of CYP2C19 in Colombian mestizo nidividuals</article-title><source><italic>BMC Clinical Pharmacology</italic></source><year>2007</year><volume>7, article no. 6</volume><pub-id pub-id-type="other">2-s2.0-34548616410</pub-id><pub-id pub-id-type="doi">10.1186/1472-6904-7-6</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>H.-R.</given-names></name><name><surname>Poland</surname><given-names>R. E.</given-names></name><name><surname>Lin</surname><given-names>K.-M.</given-names></name><name><surname>Wan</surname><given-names>Y.-J. Y.</given-names></name></person-group><article-title>Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study</article-title><source><italic>Clinical Pharmacology and Therapeutics</italic></source><year>2006</year><volume>80</volume><issue>1</issue><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2006.03.003</pub-id><pub-id pub-id-type="other">2-s2.0-33745418092</pub-id><pub-id pub-id-type="pmid">16815315</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>M. P.</given-names></name><name><surname>Sellers</surname><given-names>E. M.</given-names></name><name><surname>Tyndale</surname><given-names>R. F.</given-names></name></person-group><article-title>Canadian Native Indians exhibit unique CTP2A6 and CTP2C19 mutant allele frequencies</article-title><source><italic>Clinical Pharmacology and Therapeutics</italic></source><year>1998</year><volume>64</volume><issue>4</issue><fpage>378</fpage><lpage>383</lpage><pub-id pub-id-type="other">2-s2.0-0031714780</pub-id><pub-id pub-id-type="doi">10.1016/S0009-9236(98)90068-6</pub-id><pub-id pub-id-type="pmid">9797794</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdy</surname><given-names>S. I.</given-names></name><name><surname>Hiratsuka</surname><given-names>M.</given-names></name><name><surname>Narahara</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population</article-title><source><italic>British Journal of Clinical Pharmacology</italic></source><year>2002</year><volume>53</volume><issue>6</issue><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="other">2-s2.0-0035987174</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.01604.x</pub-id><pub-id pub-id-type="pmid">12047484</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bathum</surname><given-names>L.</given-names></name><name><surname>Skjelbo</surname><given-names>E.</given-names></name><name><surname>Mutabingwa</surname><given-names>T. K.</given-names></name><name><surname>Madsen</surname><given-names>H.</given-names></name><name><surname>H&#x000f8;rder</surname><given-names>M.</given-names></name><name><surname>Br&#x000f8;sen</surname><given-names>K.</given-names></name></person-group><article-title>Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population</article-title><source><italic>British Journal of Clinical Pharmacology</italic></source><year>1999</year><volume>48</volume><issue>3</issue><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="other">2-s2.0-0032868321</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.1999.00019.x</pub-id><pub-id pub-id-type="pmid">10510152</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khedhaier</surname><given-names>A.</given-names></name><name><surname>Hassen</surname><given-names>E.</given-names></name><name><surname>Bouaouina</surname><given-names>N.</given-names></name><name><surname>Gabbouj</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>S. B.</given-names></name><name><surname>Chouchane</surname><given-names>L.</given-names></name></person-group><article-title>Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma</article-title><source><italic>BMC Cancer</italic></source><year>2008</year><volume>8, article no. 109</volume><pub-id pub-id-type="doi">10.1186/1471-2407-8-109</pub-id><pub-id pub-id-type="other">2-s2.0-43749116210</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allabi</surname><given-names>A. C.</given-names></name><name><surname>Gala</surname><given-names>J.-L.</given-names></name><name><surname>Desager</surname><given-names>J.-P.</given-names></name><name><surname>Heusterspreute</surname><given-names>M.</given-names></name><name><surname>Horsmans</surname><given-names>Y.</given-names></name></person-group><article-title>Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations</article-title><source><italic>British Journal of Clinical Pharmacology</italic></source><year>2003</year><volume>56</volume><issue>6</issue><fpage>653</fpage><lpage>657</lpage><pub-id pub-id-type="other">2-s2.0-0344512432</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01937.x</pub-id><pub-id pub-id-type="pmid">14616425</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namazi</surname><given-names>S.</given-names></name><name><surname>Azarpira</surname><given-names>N.</given-names></name><name><surname>Hendijani</surname><given-names>F.</given-names></name><name><surname>Khorshid</surname><given-names>M. B.</given-names></name><name><surname>Vessal</surname><given-names>G.</given-names></name><name><surname>Mehdipour</surname><given-names>A. R.</given-names></name></person-group><article-title>The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran</article-title><source><italic>Clinical Therapeutics</italic></source><year>2010</year><volume>32</volume><issue>6</issue><fpage>1050</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2010.06.010</pub-id><pub-id pub-id-type="other">2-s2.0-77954648173</pub-id><pub-id pub-id-type="pmid">20637959</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassar</surname><given-names>S.</given-names></name><name><surname>Amro</surname><given-names>O.</given-names></name><name><surname>Abu-Rmaileh</surname><given-names>H.</given-names></name><name><surname>Alshaer</surname><given-names>I.</given-names></name><name><surname>Korachi</surname><given-names>M.</given-names></name><name><surname>Ayesh</surname><given-names>S.</given-names></name></person-group><article-title>ABCB1 C3435T and CYP2C19&#x02217;2 polymorphisms in a Palestinian and Turkish population: a pharmacogenetic perspective to clopidogrel</article-title><source><italic>Meta Gene</italic></source><year>2014</year><volume>2</volume><issue>1</issue><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.mgene.2014.01.009</pub-id><pub-id pub-id-type="other">2-s2.0-84901790006</pub-id><pub-id pub-id-type="pmid">25606414</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>S.</given-names></name><name><surname>Sibbing</surname><given-names>D.</given-names></name><name><surname>Braun</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents</article-title><source><italic>American Heart Journal</italic></source><year>2010</year><volume>160</volume><issue>2</issue><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="other">2-s2.0-77955465123</pub-id><pub-id pub-id-type="doi">10.1016/j.ahj.2010.05.003</pub-id><pub-id pub-id-type="pmid">20691843</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oikawa</surname><given-names>Y.</given-names></name><name><surname>Yajima</surname><given-names>J.</given-names></name><name><surname>Costa</surname><given-names>M. A.</given-names></name><etal/></person-group><article-title>Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential &#x02018;thromborestenosis&#x02019; phenomenon</article-title><source><italic>EuroIntervention</italic></source><year>2010</year><volume>6</volume><issue>3</issue><fpage>380</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.4244/EIJV6I3A63</pub-id><pub-id pub-id-type="other">2-s2.0-79952778553</pub-id><pub-id pub-id-type="pmid">20884418</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishio</surname><given-names>R.</given-names></name><name><surname>Shinke</surname><given-names>T.</given-names></name><name><surname>Otake</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel</article-title><source><italic>Circulation Journal</italic></source><year>2012</year><volume>76</volume><issue>10</issue><fpage>2348</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-12-0476</pub-id><pub-id pub-id-type="other">2-s2.0-84867846431</pub-id><pub-id pub-id-type="pmid">22785462</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>T.</given-names></name><name><surname>Shinke</surname><given-names>T.</given-names></name><name><surname>Shite</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Impact of cytochrome P450 2C19&#x02217;2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel</article-title><source><italic>Circulation Journal</italic></source><year>2011</year><volume>75</volume><issue>1</issue><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-10-0525</pub-id><pub-id pub-id-type="other">2-s2.0-78651242921</pub-id><pub-id pub-id-type="pmid">21099121</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozari</surname><given-names>Y.</given-names></name><name><surname>Vosooghi</surname><given-names>S.</given-names></name><name><surname>Boroumand</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: a case-match study</article-title><source><italic>The Anatolian Journal of Cardiology</italic></source><year>2015</year><volume>15</volume><issue>5</issue><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.5152/akd.2014.5418</pub-id><pub-id pub-id-type="other">2-s2.0-84929306249</pub-id><pub-id pub-id-type="pmid">25993709</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>D. J.</given-names></name><name><surname>Kwon</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>A.-R.</given-names></name><etal/></person-group><article-title>Association of CYP2C19&#x02217;2 and &#x02217;3 genetic variants with essential hypertension in Koreans</article-title><source><italic>Yonsei Medical Journal</italic></source><year>2012</year><volume>53</volume><issue>6</issue><fpage>1113</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.3349/ymj.2012.53.6.1113</pub-id><pub-id pub-id-type="other">2-s2.0-84868135101</pub-id><pub-id pub-id-type="pmid">23074110</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y.-J.</given-names></name><name><surname>Li</surname><given-names>J.-W.</given-names></name><name><surname>Zhang</surname><given-names>M.-J.</given-names></name><etal/></person-group><article-title>The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment</article-title><source><italic>CNS Neuroscience and Therapeutics</italic></source><year>2014</year><volume>20</volume><issue>2</issue><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="other">2-s2.0-84892529729</pub-id><pub-id pub-id-type="doi">10.1111/cns.12173</pub-id><pub-id pub-id-type="pmid">24330577</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elezi</surname><given-names>S.</given-names></name><name><surname>Kastrati</surname><given-names>A.</given-names></name><name><surname>Pache</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>1998</year><volume>32</volume><issue>7</issue><fpage>1866</fpage><lpage>1873</lpage><pub-id pub-id-type="other">2-s2.0-0032406132</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(98)00467-7</pub-id><pub-id pub-id-type="pmid">9857865</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastrati</surname><given-names>A.</given-names></name><name><surname>Sch&#x000f6;mig</surname><given-names>A.</given-names></name><name><surname>Elezi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Predictive factors of restenosis after coronary stent placement</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>1997</year><volume>30</volume><issue>6</issue><fpage>1428</fpage><lpage>1436</lpage><pub-id pub-id-type="other">2-s2.0-0343852702</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(97)00334-3</pub-id><pub-id pub-id-type="pmid">9362398</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritsinger</surname><given-names>V.</given-names></name><name><surname>Saleh</surname><given-names>N.</given-names></name><name><surname>Lagerqvist</surname><given-names>B.</given-names></name><name><surname>Norhammar</surname><given-names>A.</given-names></name></person-group><article-title>High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus</article-title><source><italic>Circulation: Cardiovascular Interventions</italic></source><year>2015</year><volume>8</volume><issue>6</issue><pub-id pub-id-type="other">2-s2.0-84937621965</pub-id><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.002328</pub-id><pub-id pub-id-type="publisher-id">e002328</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossington</surname><given-names>J. A.</given-names></name><name><surname>Brown</surname><given-names>O. I.</given-names></name><name><surname>Hoye</surname><given-names>A.</given-names></name></person-group><article-title>Systematic review and meta-analysis of optimal P2Y<sub>12</sub> blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome</article-title><source><italic>Open Heart</italic></source><year>2016</year><volume>3</volume><pub-id pub-id-type="publisher-id">e000296</pub-id><pub-id pub-id-type="doi">10.1136/openhrt-2015-000296</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angiolillo</surname><given-names>D. J.</given-names></name><name><surname>Jakubowski</surname><given-names>J. A.</given-names></name><name><surname>Ferreiro</surname><given-names>J. L.</given-names></name><etal/></person-group><article-title>Impaired responsiveness to the platelet P2Y<sub>12</sub> receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2014</year><volume>64</volume><issue>10</issue><fpage>1005</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.06.1170</pub-id><pub-id pub-id-type="other">2-s2.0-84908205601</pub-id><pub-id pub-id-type="pmid">25190236</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreras</surname><given-names>E. T.</given-names></name><name><surname>Hochholzer</surname><given-names>W.</given-names></name><name><surname>Frelinger</surname><given-names>A. L.</given-names></name><etal/></person-group><article-title>Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel: insights from the ELEVATE-TIMI 56 trial</article-title><source><italic>Thrombosis and Haemostasis</italic></source><year>2016</year><volume>116</volume><issue>1</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1160/TH15-12-0981</pub-id><pub-id pub-id-type="other">2-s2.0-84977570974</pub-id><pub-id pub-id-type="pmid">27009617</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jukema</surname><given-names>J. W.</given-names></name><name><surname>Verschuren</surname><given-names>J. J. W.</given-names></name><name><surname>Ahmed</surname><given-names>T. A. N.</given-names></name><name><surname>Quax</surname><given-names>P. H. A.</given-names></name></person-group><article-title>Restenosis after PCI. Part 1: pathophysiology and risk factors</article-title><source><italic>Nature Reviews Cardiology</italic></source><year>2012</year><volume>9</volume><issue>1</issue><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2011.132</pub-id><pub-id pub-id-type="other">2-s2.0-83655167286</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stettler</surname><given-names>C.</given-names></name><name><surname>Wandel</surname><given-names>S.</given-names></name><name><surname>Allemann</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis</article-title><source><italic>Lancet</italic></source><year>2007</year><volume>370</volume><issue>9591</issue><fpage>937</fpage><lpage>948</lpage><pub-id pub-id-type="other">2-s2.0-34548542073</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61444-5</pub-id><pub-id pub-id-type="pmid">17869634</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirtane</surname><given-names>A. J.</given-names></name><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Iyengar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies</article-title><source><italic>Circulation</italic></source><year>2009</year><volume>119</volume><issue>25</issue><fpage>3198</fpage><lpage>3206</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.826479</pub-id><pub-id pub-id-type="other">2-s2.0-67650755016</pub-id><pub-id pub-id-type="pmid">19528338</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical and demographic characteristics of the study group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Patients with restenosis</th><th align="center" rowspan="1" colspan="1">Controls</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 77</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 86</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">62.75 &#x000b1; 9.8</td><td align="center" rowspan="1" colspan="1">65.45 &#x000b1; 9.8</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Male (%)</td><td align="center" rowspan="1" colspan="1">80.5</td><td align="center" rowspan="1" colspan="1">72.1</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27.6 &#x000b1; 3.8</td><td align="center" rowspan="1" colspan="1">28.0 &#x000b1; 3.35</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">131.4 &#x000b1; 22.2</td><td align="center" rowspan="1" colspan="1">135.0 &#x000b1; 26</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">72.58 &#x000b1; 14.0</td><td align="center" rowspan="1" colspan="1">72.47 &#x000b1; 14.3</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="center" rowspan="1" colspan="1">69.4 &#x000b1; 14.5</td><td align="center" rowspan="1" colspan="1">69.1 &#x000b1; 14.3</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">135.3 &#x000b1; 63.6</td><td align="center" rowspan="1" colspan="1">117.0 &#x000b1; 42.5</td><td align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (%)</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia (%)</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">159.0 &#x000b1; 49.0</td><td align="center" rowspan="1" colspan="1">181.9 &#x000b1; 128.0</td><td align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">160.4 &#x000b1; 145.4</td><td align="center" rowspan="1" colspan="1">159.9 &#x000b1; 85.8</td><td align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C (mg/dL)</td><td align="center" rowspan="1" colspan="1">96.38 &#x000b1; 54.0</td><td align="center" rowspan="1" colspan="1">99.40 &#x000b1; 38.5</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C (mg/dL)</td><td align="center" rowspan="1" colspan="1">40.78 &#x000b1; 16.1</td><td align="center" rowspan="1" colspan="1">36.62 &#x000b1; 7.9</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking (%)</td><td align="center" rowspan="1" colspan="1">77.8</td><td align="center" rowspan="1" colspan="1">69.0</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction (%)</td><td align="center" rowspan="1" colspan="1">45.6</td><td align="center" rowspan="1" colspan="1">32.9</td><td align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.98 &#x000b1; 0.28</td><td align="center" rowspan="1" colspan="1">1.02 &#x000b1; 0.68</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">6.58 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">6.40 &#x000b1; 1.25</td><td align="center" rowspan="1" colspan="1">0.23</td></tr></tbody></table><table-wrap-foot><fn><p>Values expressed as mean &#x000b1; standard deviation. SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; TG: triglycerides; HbA1c: glycosylated hemoglobin; HR: heart rate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Angiographic characteristics of the study group according to the development of in-stent restenosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Patients with restenosis</th><th align="center" rowspan="1" colspan="1">Controls</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 77</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic> = 86</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Lesion</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute (%)</td><td align="center" rowspan="1" colspan="1">38.8</td><td align="center" rowspan="1" colspan="1">55.6</td><td rowspan="2" align="center" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic (%)</td><td align="center" rowspan="1" colspan="1">61.2</td><td align="center" rowspan="1" colspan="1">44.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Diameter (mm)</td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 0.45</td><td align="center" rowspan="1" colspan="1">2.9 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Length (mm)</td><td align="center" rowspan="1" colspan="1">21.5 &#x000b1; 5.4</td><td align="center" rowspan="1" colspan="1">21.4 &#x000b1; 5.4</td><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Lesion vessel (%)</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">LMCA</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">LAD</td><td align="center" rowspan="1" colspan="1">58.7</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">CX</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">20.4</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">RCA</td><td align="center" rowspan="1" colspan="1">26.7</td><td align="center" rowspan="1" colspan="1">29.6</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Stent type (%)</italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">DES</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">27.7</td><td rowspan="2" align="center" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">BMS</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">72.3</td></tr></tbody></table><table-wrap-foot><fn><p>LMCA: left main coronary artery; LAD: left anterior descending artery; CX: circumflex artery; RCA: right coronary artery; BMS: bare-metal stent; DES: drug-eluting stent.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Genotypic distribution, relative allele frequencies, and odds ratio (OR) for the CYP2C19<sup><italic>&#x02217;</italic></sup>2 variant in Chilean patients with and without restenosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Polymorphism<break/>rs4244285</th><th colspan="3" align="center" rowspan="1">Genotypes</th><th colspan="2" align="center" rowspan="1">Allele frequency</th></tr><tr><th align="center" rowspan="1" colspan="1">GG</th><th align="center" rowspan="1" colspan="1">AG</th><th align="center" rowspan="1" colspan="1">AA</th><th align="center" rowspan="1" colspan="1">G</th><th align="center" rowspan="1" colspan="1">A</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cases, <italic>n</italic> = 77</td><td align="center" rowspan="1" colspan="1">69 (89.6%)</td><td align="center" rowspan="1" colspan="1">8 (10.4%)</td><td align="center" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" rowspan="1" colspan="1">0.95 (146)</td><td align="center" rowspan="1" colspan="1">0.05 (8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Controls, <italic>n</italic> = 86</td><td align="center" rowspan="1" colspan="1">68 (79.0%)</td><td align="center" rowspan="1" colspan="1">17 (19.8%)</td><td align="center" rowspan="1" colspan="1">1 (1.2%)</td><td align="center" rowspan="1" colspan="1">0.90 (153)</td><td align="center" rowspan="1" colspan="1">0.10 (19)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>p</italic> value</td><td colspan="3" align="center" rowspan="1">0.150 (<italic>&#x003c7;</italic><sup>2</sup> = 3.76)</td><td colspan="2" align="center" rowspan="1">0.055 (<italic>&#x003c7;</italic><sup>2</sup> = 3.66)</td></tr><tr><td align="left" rowspan="1" colspan="1">Odds ratio</td><td colspan="3" align="center" rowspan="1">0.44 (95% CI: 0.19&#x02013;1.04); <italic>p</italic> = 0.06</td><td colspan="2" align="center" rowspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>n</italic>: number of individuals. Genotype frequency values given as percentage. <italic>p</italic> value calculated by chi-square. CI: confidence interval. HWE (cases: <italic>&#x003c7;</italic><sup>2</sup> = 0.23; <italic>p</italic> = 0.63; controls: <italic>&#x003c7;</italic><sup>2</sup> = 0.002; <italic>p</italic> = 0.95).</p></fn></table-wrap-foot></table-wrap></floats-group></article>